Paul has over 25 years’ experience across the life sciences sector; encompassing technical, commercial and financial areas. With a career spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance; Paul has expertise in public listings, capital raising, business development, product development & commercialization and sales & marketing. He has a founded life sciences start-ups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Paul has previously served as Managing Director, Executive and Non-Executive Director or CEO of several VC funded, ASX, NASDAQ, CSE and TSX listed companies. Paul is currently Chairman of AdAlta Ltd and Non-Executive Director of Sypharma Pty Limited as well as serving on Australian federal government committees.
David Foster, PhD, JD
President, Board Member
David Foster, PhD, JD is involved with a number of biotech startups. He has more than 18 years legal experience working as patent counsel in international law firms as well as in-house at Medarex, a biopharmaceutical company acquired by Bristol-Myers Squibb. David has identified foundational and complementary IP and coordinated licensing programs to supplement IP strategies for numerous products. David currently serves as partner of Roberts Foster LLP, a law firm focusing on emerging technology companies, and on the Board of BioNorthTx, a regional life science trade association he co-founded. David received his Ph.D. from The University of Texas Southwestern Medical Center and J.D. from Golden Gate University School of Law.
William J. Garner, MD MPH
William J. Garner is a physician, investor and entrepreneur. As Managing Director of EGB Ventures, he has made numerous public and private investments. Bill was the founder and Chairman of Race Oncology (ASX:RAC). Bill is currently Chairman of InMed Pharmaceuticals, Inc. (TSX:IN), and Artos Pharmaceuticals, Inc. He has a Master of Public Health from Harvard and received his M.D. degree from New York Medical College. Dr. Garner did residency training in Anatomic Pathology at Columbia-Presbyterian and is currently a licensed physician.
Joe is Managing Director at Edison Group and has over ten years of experience in investor relations, focusing primarily on the healthcare sector. He began his career at Porter, LeVay & Rose as a generalist in investor relations then joined the Ruth Group three years later, specializing in investor relations for healthcare companies. Over the next four years, Joe built extensive buy-side, sell-side and advisory networks, focusing on non-deal roadshows and events, including coverage of the annual JP Morgan Healthcare Conference.
Al Hansen, MBA
Al Hansen is an experienced business investor and executive with over 30 years experience in small company investments and investment banking. He is currently CEO/founder of KESA Partners Inc., which invests in small drug and medical device companies. Formerly, as a partner with Signet Healthcare Partners, he was Chairman of Questcor Pharmaceuticals (sold to Mallinkrodt for $5 billion), Chairman of Cedarburg Pharmaceuticals (sold to Albany Molecular for over $40 million) and Chairman of Molecular Medicine Bioservices (sold to SAFC for over $20 million.) He was formerly a principal with Darby Overseas (now a part of Franklin Templeton.) He was also Director of Corporate Finance at the US Treasury. He was an investment banker with Dillon Read and E.F. Hutton. He also served as a Special Forces officer in the U.S. Army. He holds an M.B.A. (with distinction) from the Wharton School and an A.B. from Princeton University.